Objectives: Approximately 250,000 patients per year are admitted to hospitals in the United Kingdom (UK) with skin and soft tissue (SSTI) infections, accounting for ~1.6% of hospital admissions. Staphylococcus aureus accounts for >50% of SSTIs; methicillin-resistant Staphylococcus aureus(MRSA) infections represent approximately 13.7% of those. Treatment of SSTIs is costly and often involves intravenous (IV) antibiotic therapy, hospitalization of ≥10 days and may involve both inpatient stay and multi-day follow-up outpatient antibiotic parenteral therapy (OPAT). Hospitals and healthcare systems may reduce the economic burden of hospitalized patients through the use of OPAT and/or early hospital discharge. Oritavancin is a single, once-only 1200 mg IV dose for the treatment of SSTIs caused by gram positive bacteria, including MRSA. The aim of this analysis was to quantify the annual economic impact to a UK hospital of using oritavancin in select moderate-tosevere SSTI patients.
• Outpatient treatment and/or early hospital discharge may be utilized to avoid hospitalization and to reduce inpatient length of stay (LOS) and associated hospital costs. 5 • Oritavancin is indicated as a single, once-only 1200 mg IV dose for the treatment of patients with SSTIs caused by susceptible isolates of designated gram-positive bacteria, including MRSA.
• The aim of our analysis was to evaluate the economic impact of using oritavancin for select moderate-tosevere SSTI patients requiring IV antibiotics from a UK hospital perspective.
-The model allows an individual hospital to estimate the budget impact of using oritavancin in both the inpatient and outpatient setting.
-Eron is a clinical consensus algorithm that categorizes SSTI infections into four classes of ascending severity and forms the basis of the UK and CREST guidelines. The target patient for oritavancin most closely aligns to Eron class II and III (moderate-to-severe) patients. 6 -Patients within these classes are characterized by an ill or toxic appearance with few or no comorbidities and do not exhibit sepsis syndrome or a life-threatening infection.
-47% of SSTI patients in the UK are reported to receive IV antibiotics. 7 • A decision analytic model based on current clinical practice was developed to simulate treatment of SSTI patients with suspected or confirmed MRSA (Figure 1 ).
• The perspective of the model is from a UK hospital whose patients currently return to a hospital-owned setting for outpatient treatment (e.g., a hospital-owned ambulatory infusion center).
• The model simulates a cohort of 100 SSTI patients receiving MRSA-active antibiotics per year and costs include the index treatment episode and 30-day re-hospitalization.
• Clinical inputs were derived from a literature search, a network meta-analysis (NMA) and oritavancin's pivotal phase III studies (Table 1 ).
• Health resources were informed by published sources and expert opinion ( Table 2 ).
• Drug costs were based on British National Formulary. 8 Oritavacin drug cost was based on the US price (Table 3 ).
• Other included costs were based on the UK 2012/2013 NHS reference costs. 9 • All costs were inflated to 2014 values using the medical Consumer Price Index (CPI). 10 • The base case reflects the national average usage of MRSA-active antibiotics (Table 1, Figure1 ).
• In the scenario case, oritavancin was assumed to be used in 3.6% of patients, representing a conservative estimate for moderate-to-severe SSTI (Eron class II and III).
Methods

Results
• Using oritavancin conservatively (3.6% of patients) for the treatment of moderate-severe SSTI with suspected or confirmed MRSA is estimated to reduce total hospital cost by £29.23/patient:
-Cost savings were derived from shifting patient care to the outpatient setting and allowing for early discharge.
-Drug cost increases were offset by reductions in other costs (i.e. adverse events, drug administration, lab costs and hospitalizations).
-Both inpatient and outpatient days of treatment were reduced.
Conclusions
• Oritavancin was assumed to be used in 3.6% of SSTI patients in the scenario, representing moderate-to-severe patients.
• Reductions of 0.1 AEs and 20.9 of laboratory testing was estimated in the scenario (Figure 2 ).
• Inpatient and outpatient days of treatment were reduced by shifting care to the outpatient setting with use of oritavancin in the scenario (Figure 3 ).
• The budget impact model results indicate that, in a cohort of 100 SSTI patients eligible for IV MRSA antibiotics/year, using oritavancin in moderate-severe SSTI • This calculation is inclusive of inpatient and outpatient costs. At the current US price of $2900 for oritavancin:
-Pharmaceutical costs were increased by £61.12 per patient.
-Drug administration costs were reduced by £55.31 per patient.
-Hospitalization/Outpatient costs were reduced by £33.80. Vancomycin IV 82.2% 11 10 12 Daptomycin IV 90.0% 11 10 12 Linezolid IV 87.0% 11 10 12 Oritavancin IV 82.9% 11 1 12 Ceftriaxone IV 82.2% 11 10 12 Teicoplanin IV 75.3% 11 10 12 Description Cost 
